FDG PET(及MRI)用于监测阿尔茨海默病免疫治疗
本文讨论阿尔茨海默病被动免疫治疗中淀粉样蛋白PET评估的可靠性,认为所观察到的可能主要是白质内非特异性淀粉样蛋白PET信号在免疫治疗中减弱,与淀粉样蛋白相关影像异常剂量依赖性增加及治疗组较安慰剂组脑体积丢失增加一致。作者建议在所有未来免疫治疗试验中重复进行FDG PET和MRI。
要点
- 作者质疑淀粉样蛋白PET所评估的淀粉样蛋白清除证据的有效性。
- 作者认为观察到的更可能是白质内大量非特异性淀粉样蛋白PET信号在免疫治疗中减弱。
- 作者建议所有未来免疫治疗试验重复进行FDG PET和MRI。
核心结论
- 作者质疑淀粉样蛋白PET所评估的淀粉样蛋白清除证据的有效性,认为观察到的更可能是白质内大量非特异性淀粉样蛋白PET信号在免疫治疗中减弱。
- 作者建议在所有未来免疫治疗试验中重复进行FDG PET和MRI。
研究设计与样本
- 本文为针对阿尔茨海默病被动免疫治疗中淀粉样蛋白PET评估证据的论述性文章。
主要发现
- 作者认为淀粉样蛋白PET所见的信号减弱更可能是白质内大量非特异性淀粉样蛋白PET信号在免疫治疗中减弱。
- 作者提到该现象与淀粉样蛋白相关影像异常呈剂量依赖性增加以及治疗组较安慰剂组脑体积丢失增加一致。
临床怎么用
- 作者建议在所有未来免疫治疗试验中重复进行FDG PET和MRI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Passive immunotherapy for Alzheimer disease has been tried for over 10 years without success. However, in 2021 and most recently in January 2023, the US Food and Drug Administration granted accelerated approval of 2 antibodies for this purpose, aducanumab and lecanemab. In both cases, the approval was based on a presumed therapy-related removal of amyloid deposits from the brain and, in the case of lecanemab, also some delay in cognitive decline. We question the validity of the evidence for the removal of amyloid in particular as assessed by amyloid PET imaging, believing that what is observed is more likely a large nonspecific amyloid PET signal in the white matter that diminishes during immunotherapy-in line with dose-dependent increases in amyloid-related imaging abnormalities and increased loss of cerebral volume in treated compared with placebo patients. To investigate this further, we recommend repeat FDG PET and MRI in all future immunotherapy trials.
引用
- Høilund-Carlsen PF, Revheim ME, Alavi A, et al. FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease. Clin Nucl Med. 2023. PMID: 37314733. doi:10.1097/RLU.0000000000004710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。